Vosaroxin and Azacitidine in Treating Patients With Myelodysplastic Syndromes
A Phase I Study of Vosaroxin Plus Azacitidine for Patients With Myelodysplastic Syndrome
Sponsor: Sunesis Pharmaceuticals
Listed as NCT01913951, this PHASE1 trial focuses on Myelodysplastic Syndromes and remains completed. Sponsored by Sunesis Pharmaceuticals, it has been updated 17 times since 2013, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
17 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jun 2024 — Jul 2024 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
May 2024 — Jun 2024 [monthly]
Active Not Recruiting PHASE1
▶ Show 12 earlier versions
-
Apr 2023 — May 2024 [monthly]
Active Not Recruiting PHASE1
-
Apr 2022 — Apr 2023 [monthly]
Active Not Recruiting PHASE1
-
Sep 2021 — Apr 2022 [monthly]
Active Not Recruiting PHASE1
-
Jan 2021 — Sep 2021 [monthly]
Active Not Recruiting PHASE1
-
Jul 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE1
-
Jul 2019 — Jul 2020 [monthly]
Active Not Recruiting PHASE1
-
Jul 2018 — Jul 2019 [monthly]
Active Not Recruiting PHASE1
-
Jun 2018 — Jul 2018 [monthly]
Active Not Recruiting PHASE1
-
Aug 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE1
-
May 2017 — Aug 2017 [monthly]
Active Not Recruiting PHASE1
-
Feb 2017 — May 2017 [monthly]
Active Not Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE1
First recorded
Nov 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Sunesis Pharmaceuticals
- Washington University School of Medicine
For direct contact, visit the study record on ClinicalTrials.gov .